Amgen's revenue has grown 10.5% over the past 4 quarters, reaching $9.9B in the most recent period. Net income has expanded by 84.2% year-over-year to $7.7B. This robust profitability is evidenced by Amgen's expanding net margin, which has climbed from 21.0% to 21.0% over the same timeframe. Amgen's exceptional growth is being driven by strong demand for its diversified portfolio of biologics and small molecule drugs. The company's ROIC has also improved from 13.9% to 13.9% over the past year, indicating efficient capital allocation. Amgen's balance sheet remains solid, with $9.1B in cash and $54.6B in debt. Looking ahead, I expect Amgen's momentum to continue as new product launches and pipeline advancements boost revenue and earnings. The company's strong free cash flow generation, which has grown 10.7% year-over-year, provides ample flexibility for further investment in R&D and shareholder-friendly initiatives. At the current share price of $349.77, Amgen trades at 24.5x forward earnings and 1.8x EV/Revenue. This attractive valuation, combined with the company's robust financial profile and growth prospects, makes Amgen a compelling investment opportunity. I have a 7/10 conviction in this bullish thesis.

Research these companies